Key Highlights

• NVS shares rose 2.88% intraday to $158.58.

• The European Commission granted marketing authorization for Itvisma, a gene replacement therapy for spinal muscular atrophy.

• Itvisma is the first and only gene therapy approved in the EU for SMA patients aged two and older.

• Novartis carries a market capitalization of approximately $302.59 billion, ahead of its July 18 earnings report.

EU Approval Expands Gene Therapy Franchise

Novartis AG (NYSE:NVS) shares rose sharply Thursday after the European Commission granted marketing authorization for Itvisma (onasemnogene abeparvovec), the company's gene replacement therapy for spinal muscular atrophy patients aged two and older, making it the first and only gene therapy approved for this broader SMA patient population in the European Union.

Novartis is a Basel, Switzerland-based multinational pharmaceutical corporation operating as a pure-play innovative medicines company, concentrating its research, development and commercialization efforts across oncology, immunology, cardiovascular-renal-metabolic diseases, neuroscience and rare diseases.

Approval Expands Existing SMA Franchise

The Itvisma approval expands Novartis's already dominant spinal muscular atrophy franchise alongside its existing Zolgensma therapy, addressing a significant unmet medical need for older SMA patients who previously lacked access to gene replacement treatment. Investor sentiment was further supported by upward price target revisions from multiple financial firms ahead of the company's July 18 earnings report.

Novartis currently trades at a market capitalization exceeding $302.59 billion, with a price-to-earnings ratio near 18.3 and a dividend yield of 2.89%. The company's blockbuster portfolio includes Entresto, Cosentyx, Kisqali and Pluvicto, generating combined net sales of approximately $50 billion to $55 billion in 2024.

Conclusion

The EU approval of Itvisma reinforces Novartis's leadership position in spinal muscular atrophy treatment, expanding access to gene therapy for a broader patient population. With the company's second-quarter earnings report approaching on July 18, continued execution across its five core therapeutic areas will remain the primary focus for investors.

 

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.